Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.8036
-0.0002-0.02%
Volume:278.22K
Turnover:219.74K
Market Cap:25.16M
PE:-0.26
High:0.8100
Open:0.8000
Low:0.7760
Close:0.8038
52wk High:5.25
52wk Low:0.7365
Shares:31.31M
Float Shares:26.89M
Volume Ratio:1.19
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.22
PE(LYR):-0.14

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

BioXcel Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

BioXcel Therapeutics issues warrants for 1,353,729 shares at $0.01 exercise price

Reuters
·
Apr 18

BioXcel Therapeutics to host virtual event on IGALMI at-home launch plan

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

Reuters
·
Apr 08

BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims

Reuters
·
Apr 08

BioXcel Therapeutics enrolls first patients in BXCL501 trial

TIPRANKS
·
Apr 08

BioXcel enrolls first patients in DoW-funded Phase 2a BXCL501 acute stress trial

Reuters
·
Apr 08

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of Bxcl501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

THOMSON REUTERS
·
Apr 08

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of Igalmi® in the at-Home Setting

THOMSON REUTERS
·
Apr 01

BioXcel Therapeutics Inc - FDA Assigns Pdufa Target Action Date of November 14, 2026 for Igalmi Application - SEC Filing

THOMSON REUTERS
·
Apr 01

BioXcel says FDA accepts IGALMI sNDA for at-home agitation treatment

Reuters
·
Apr 01

Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
Mar 30

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 28

AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs

Reuters
·
Mar 27

BioXcel Therapeutics FY2025 net revenue drops 72% to $642,000; net loss widens to $69.9 million

Reuters
·
Mar 27

BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75

Reuters
·
Mar 27

BioXcel Therapeutics Q4 Revenue USD 256 Thousand VS. Ibes Estimate USD 162 Thousand

THOMSON REUTERS
·
Mar 27

BioXcel Therapeutics Q4 Operating Expenses USD 10.538 Million

THOMSON REUTERS
·
Mar 27